Aviragen Therapeutics (AVIR) Misses Q4 EPS Views

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.18), $0.43 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $60 thousand versus the consensus estimate of $21 million.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Dell’s earning report was bullish for Intel CPU demand, analyst says
• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg